Brookline Capital Markets launched coverage of electroCore (NASDAQ:ECOR) with a “buy” rating and price target of $5. The stock closed at $1.57 on Oct. 22. electroCore is a bioelectronic medicine company whose lead...
Brookline Capital Markets added Sally Yanchus and Leah Rush Cann to its life sciences equity research team. With the addition of Ms. Yanchus and Ms. Cann, Brookline now has three publishing life sciences analysts, as...
Brookline Capital Markets initiated coverage of Biocept (NASDAQ:BIOC) with a “buy” rating and price target of $2.06. The stock closed at 44 cents on May 13. Biocept is a molecular oncology diagnostics company that...
Brookline Capital Markets initiated coverage of Bellerophon Therapeutics (NASDAQ:BLPH) with a “buy” rating and $35 price target. The stock closed at $11.91 on April 13. Bellerophon is developing inhaled nitric oxide...
Brookline Capital Markets initiated coverage of BioCeres Crop Solutions (NASDAQ:BIOX) with a “buy” rating and $13 price target. The stock closed at $4.95 on Feb. 4. BioCeres is the market leader in South America...